Palliative sedation therapy for terminal movement disorders.
Daniel Kent PartainApril ZehmPublished in: BMJ supportive & palliative care (2020)
Palliative sedation therapy (PST) can be a challenging area of palliative medicine because of the complex ethical considerations involved. PST is a medical therapy used for refractory symptoms in terminally ill patients and is often considered ethically justified due to the principle of double effect. Even in cases where PST is clearly indicated such as refractory cancer pain, there is potential for moral distress among clinicians. Here, we present a unique case in which multiple therapeutic options were limited in a patient with overlapping diagnoses of catatonia, medication-induced extrapyramidal symptoms, and dementia with Lewy bodies. We review how existing frameworks can be applied to similar situations and offer practical strategies to support medical decision-making regarding PST and reduce the risk of moral distress among clinicians.
Keyphrases
- palliative care
- decision making
- advanced cancer
- healthcare
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- mild cognitive impairment
- chronic pain
- mechanical ventilation
- prognostic factors
- case report
- emergency department
- stem cells
- intensive care unit
- diabetic rats
- oxidative stress
- cognitive impairment
- physical activity
- cell therapy
- electronic health record
- drug induced
- mesenchymal stem cells
- postoperative pain
- deep brain stimulation